These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30103332)

  • 21. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
    Wang HF; Tan L; Hao XK; Jiang T; Tan MS; Liu Y; Zhang DQ; Yu JT;
    J Alzheimers Dis; 2015; 44(1):115-23. PubMed ID: 25182741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease.
    Chen Y; Therriault J; Luo J; Ba M; Zhang H; Initiative ADN
    J Integr Neurosci; 2021 Dec; 20(4):861-870. PubMed ID: 34997710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Common Variations in PLD3 on Neuroimaging Phenotypes in Non-demented Elders.
    Wang C; Wang HF; Tan MS; Liu Y; Jiang T; Zhang DQ; Tan L; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4343-51. PubMed ID: 26232066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.
    Joachim LK; Frölich L; Rüther E; Wiltfang J; Maier W; Kornhuber J; Bauer C; Heuser I; Peters O
    J Prev Alzheimers Dis; 2018; 5(3):202-206. PubMed ID: 29972214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
    Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
    Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum.
    Banning LCP; Ramakers IHGB; Köhler S; Bron EE; Verhey FRJ; de Deyn PP; Claassen JAHR; Koek HL; Middelkoop HAM; van der Flier WM; van der Lugt A; Aalten P; ;
    Am J Geriatr Psychiatry; 2020 Jul; 28(7):735-744. PubMed ID: 32088096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
    Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals.
    Paterson RW; Bartlett JW; Blennow K; Fox NC; ; Shaw LM; Trojanowski JQ; Zetterberg H; Schott JM
    Transl Psychiatry; 2014 Jul; 4(7):e419. PubMed ID: 25072324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts.
    Zhu XC; Wang HF; Jiang T; Lu H; Tan MS; Tan CC; Tan L; Tan L; Yu JT;
    Mol Neurobiol; 2017 Jan; 54(1):551-562. PubMed ID: 26742530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
    Drake JD; Chambers AB; Ott BR; Daiello LA;
    J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF and brain structural imaging markers of the Alzheimer's pathological cascade.
    Yang X; Tan MZ; Qiu A
    PLoS One; 2012; 7(12):e47406. PubMed ID: 23284610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.